Evidence map›Paper›PMID 39523731›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2025

Biomimetic Nano-delivery of Small-Molecule Piceatannol Modulates Tumor Stemness and Suppresses Colorectal Cancer Metastasis via Hippo/YAP1/SOX9 Signaling.

Minfeng Zhou, Huifang Niu, Guoquan Huang, Minquan Zhou, Dandan Cui, Huarong Li, Han Wen, Hongxing Zhang, Fengxia Liang, Rui Chen

Abstract read
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Minfeng ZhouDepartment of Integrative Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Huifang NiuJianghan University School of Medicine, 8 Triangle Lake Road, Wuhan, 430056, China.
Guoquan HuangHubei Selenium and Human Health Institute, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture. No.158 Wuyang Avenue, Enshi, Hubei Province, 445000, China.
Minquan ZhouSchool of Pharmacy and Nursing, Hubei University of Medicine, Shiyan, 442000, China.
Dandan CuiDepartment of Integrative Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Huarong LiDepartment of Integrative Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Han WenThe Second Affiliated Hospital of Shenyang Medical College, 64 West Qishan Road, Shengyang, 110036, China.
Hongxing ZhangJianghan University School of Medicine, 8 Triangle Lake Road, Wuhan, 430056, China.
Fengxia LiangSchool of Acupuncture and Bone Injury, Hubei University of Traditional Chinese Medicine, Wuhan, 430065, China.
Rui ChenDepartment of Integrative Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.ORCID 0000-0002-1587-0362

Funding

Enshi Prefecture Science and Technology Bureau, Selenium citation special D20230071National Natural Science Foundation of China 82004098National Natural Science Foundation of China 82105009National Natural Science Foundation of China 82305303National Natural Science Foundation of China 82374585Natural Science Foundation of Hubei Province 2022BCE024Natural Science Foundation of Hubei Province 2024AFD272Natural Science Foundation of Hubei Province JCZRLH202400672
6 · The paper itself

Abstract

Suppressing tumor metastasis is a crucial strategy for improving survival rates in patients with colorectal cancer (CRC), with cancer stem cells (CSCs) being the primary drivers of metastasis. Current therapeutic approaches targeting CSCs are limited, and their molecular mechanisms remain unclear. To address this challenge, a biomimetic nanoparticle delivery system, CMD-BHQ3-PTL/DOX@RBCM is developed, to deliver the stem cell regulator, piceatannol (PTL). This system used carboxymethyl dextran (CMD) and Black Hole Quencher 3 (BHQ3) to encapsulate PTL and the cytotoxic drug doxorubicin (DOX) within a red blood cell membrane (RBCm), enhancing stability and biocompatibility while allowing gradual drug release under hypoxic conditions. The effects of PTL are investigated on CSCs using molecular biology experiments, plasmid construction, and high-throughput sequencing and elucidated the molecular mechanisms underlying this biomimetic nanoparticle delivery system. The therapeutic efficacy of PTL is validated at the tissue level using subcutaneous and metastatic tumor models in human and murine systems. The results demonstrated that CMD-BHQ3-PTL/DOX@RBCM effectively addressed the challenges of specificity and biocompatibility in vivo, significantly inhibiting CSC-related tumor metastasis. This inhibitory effect is closely associated with the Hippo/YAP1/SOX9 pathway. This study highlights the effectiveness of the pH-responsive biomimetic nanoparticle system CMD-BHQ3-PTL/DOX@RBCm in delivering PTL to tumor sites, with SOX9 and its upstream Hippo/YAP1 pathway playing a critical role in the underlying mechanism.

Indexed as

Adaptor Proteins, Signal TransducingBiomimetic MaterialsBiomimeticsColorectal NeoplasmsNanoparticlesNeoplastic Stem CellsSignal TransductionSOX9 Transcription FactorStilbenesAnimalsCell Line, TumorDoxorubicinHippo Signaling PathwayHumansMiceMice, Nude3,3',4,5'-tetrahydroxystilbeneAdaptor Proteins, Signal TransducingDoxorubicinProtein Serine-Threonine KinasesSOX9 Transcription FactorStilbenesTranscription FactorsYAP1 protein, humanYAP-Signaling Proteinsbiomimetic nano‐delivery systemcancer metastasis Hippo/YAP1/SOX9 pathwaycolorectal cancer stemnesspiceatannol (PTL)

Identifiers

PMID39523731
PMCPMC11735875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.